It must have been a slow news day in Boston for The Boston Globe to repeat
ongoing rumors of Boston Scientific Corp.'s likely need to sell off assets.
The
Deal reported on the possibility of such a need back in March, when the
company first indicated it would consider an initial public offering of its
endosurgery unit. The Natick, Mass.-based medical device maker is reeling from
the debt taken on to buy rival Guidant Corp. last year.
The Globe story really doesn't offer much new insight into what could be sold.
However, it did list three technologies not on the block, including
drug-coated stents, implantable heart-rhythm devices and its small
neural-implant division. Interestingly, the story indicates that Aspect
Medical Systems Inc., a smaller medical device maker, could be put in play by
the news because Boston Scientific may sell its 27% stake in the company.
Last year, Boston Scientific bought Guidant for $27 billion after a heated
bidding war. —Matthew Wurtzel
See
story from The Boston Globe
Continue reading below
